Glycaemic Monitoring in Diabetic Kidney Disease – Is HbA1c Reliable?
DOI:
https://doi.org/10.31584/jhsmr.2021831Keywords:
diabetes, CGM, glycaemia, HbA1c, kidney diseaseAbstract
Diabetic kidney disease (DKD) is a known complication of diabetes mellitus that increases patients’ risks of developing end-stage renal failure requiring dialysis treatment and vulnerability of fatal outcomes resulted from cardiovascular events. Therefore, a good diabetic control among patients with DKD is essential. Nevertheless, monitoring glycaemia in DKD is very challenging. The use of the gold standard glycaemic marker, haemoglobin A1c (HbA1c), is complicated by many hindrances associated with both biochemical and physiological derangements of DKD. Despite the constraints, the Kidney Disease Improving Global Outcome has recommended the use of HbA1c as a reliable glycaemic marker in DKD patients, whose estimated glomerular filtration rate is down to 30 millilitres/minute per 1.73 meter2. In this article, we discuss the reliability and limitations of HbA1c as an advocated glycaemic marker in DKD. Considering that the reliability of HbA1c is highly dependent on the interpretation of the results, we also highlighted the common potential factors that can affect HbA1c interpretation in patients with DKD. The article also discusses the issues related to the utility of glycated albumin and serum fructosamine as alternative glycaemic biomarkers, and continuous glucose monitoring as a complementary marker to HbA1c in clinical practice. Understanding the HbA1c values and their limitations is important to ensure accurate interpretation of glycaemic status and to achieve optimal diabetic control in patients with DKD.
References
Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease. Clin J Am Soc Nephrol 2017;12:2032–45.
de Boer IH, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98:S1-15.
Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A view beyond HbA1c: Role of continuous glucose monitoring. Diabetes Ther 2019;10:853-63.
Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologica 2007;50:2239–44.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-701.
Presswala L, Hong S, Harris Y, Romao I, Zhang M, Jhaveri KD, et al. Continuous glucose monitoring and glycemic control in patients with type 2 Diabetes Mellitus and CKD. Kidney Med 2019;1:281–7.
Hayashi A, Takano K, Masaki T, Yoshino S, Ogawa A, Shichiri M. Distinct biomarker roles for HbA1c and glycated albumin in patients with type 2 diabetes on hemodialysis. J Diabetes Complications 2016;30:1494–9.
Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function. Diabetes Care 2014;37:1116- 23.
Vos FE, Schollum JB, Coulter C V, Manning PJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology 2012;17:182–8.
Prabhakar K, Sekhar MS, Anitha A. Glycemic variability among type 2 diabetes patients with chronic kidney disease (CKD) using continuous glucose monitoring: a study from a tertiary care hospital. J Med Sci Clin Res 2020;8:185-90.
Abd-Elrahman A, Nsr-Allah M, Kamar M, Sharawy A, Raafat N. Assessment of blood glucose variability by continuous monitoring as a therapy guide for patients with diabetic nephropathy on hemodialysis. Egypt J Intern Med 2018;30:276–83.
Riveline JP, Teynie J, Belmouaz S, Franc S, Dardari D, Bauwens M, et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: Use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009;24:2866–71.
Zelnick LR, Batacchi ZO, Ahmad I, Dighe A, Little RR, Trence DL, et al. Continuous glucose monitoring and use of alternative markers to assess glycemia in chronic kidney disease. Diabetes Care 2020;43:2379–87.
Jung M, Warren B, Grams M, Kwong YD, Shafi T, Coresh J, et al. Performance of non-traditional hyperglycemia biomarkers by chronic kidney disease status in older adults with diabetes: Results from the Atherosclerosis Risk in Communities study. J Diabetes 2018;10:276-85.
de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the 2020 KDIGO Diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020;98: 839–48.
Kwan JT, Carr EC, Barron JL, Bending MR. Carbamylated haemoglobin in normal, diabetic and uraemic patients. Ann Clin Biochem 1992;29:206-9.
Coelho S. What is the role of HbA1c in diabetic hemodialysis patients?. Semin Dial 2016;29:19–23. 18. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23:1631–4.
Coelho S, Rodrigues A. Hemoglobin A1c in patients on peritoneal dialysis: how should we interpret it?. Ther Apher Dial 2014;18:375–82.
Borg R, Persson F, Siersma V, Lind B, Olivarius NDF, Anderson CL. Interpretation of HbA1c in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database. Diabet Med 2018;35:1700–6.
Hong JW, Ku CR, Noh JH, Ko KS, Rhee BD, Kim D. Association between the presence of iron deficiency anemia and hemoglobin A1c in Korean adults The 2011 – 2012 Korea National Health and Nutrition Examination Survey. Medicine (Baltimore) 2015;94: e825.
Madhu S V, Raj A, Gupta S, Giri S, Rusia U. Effect of iron deficiency anemia and iron supplementation on HbA1c levels - Implications for diagnosis of prediabetes and diabetes mellitus in Asian Indians. Clin Chim Acta 2017;468:225–9.
Urrechaga E. The Influence of iron status in Hba1c analysis. SM J Diabetes Metab 2016;1:1004–5.
Altuntaş S , Evran M, Gürkan E, Sert M, Tetiker T. HbA1c level decreases in iron deficiency anemia. Wien Klin Wochenschr 2021;133:102-6.
Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI us commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013;62:849–59.
Kochen JA, Scimeca PG. Chronically transfused patients with increased hemoglobin A1c secondary to donor blood. Ann Clin Lab Sci 1986;16:34–7.
David H Spencer, Brenda J Grossman MGS. Letters to the editor: red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem 2011;57:344–6.
Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: Pathophysiology and clinical risk factors. Thromb Res 2006;118:417–22.
Starkman HS, Wacks M, Soeldner JS, Kim A. Effect of acute blood loss on glycosylated hemoglobin determinations in normal subjects. Diabetes Care 1983;6:291–4.
Prasad CR, Dasmohapatra DK, Panda A, Agrawal K. Postdonation variations in various hematological parameters, serum ferritin and Hba1c level in diabetic and non-diabetic donors: a study report. Indian J Pathol Oncol 2018;5:341–4.
Dijkstra A, Lenters-Westra E, De Kort W, Bokhorst AG, Bilo HJG, Slingerland RJ, et al. Whole blood donation affects the interpretation of hemoglobin A1c. PLoS One 2017;12:e0170802.
Sugimoto T, Hashimoto M, Hayakawa I, Tokuno O, Ogino T, Okuno M, et al. Alterations in HbAlc resulting from the donation of autologous blood for elective surgery in patients with diabetes mellitus. Blood Transfus 2014;12(Suppl 1): S209-13.
Aиemiї K. KDIGO Clinical Practice Guideline for Anemia in chronic kidney disease. Off J Int Soc Nephrol 2012;2:283-87.
El AZ, El-arbagy AR, Yassein YS, Khodir SZ, El H, Kasem S, et al. Effect of erythropoietin treatment on hemoglobin A1c levels in diabetic patients with chronic kidney disease. J Egypt Soc Nephrol Transplant 2019;19:86–94.
Uzu T, Hatta T, Deji N, Izumiya T, Ueda H, Miyazawa I, et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A1c. Ther Apharesis Dial 2009;13:89–94.
Mikolasevic I. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renov Dis 2017;10:35–45.
Falko JM, Dorisio TMO. Spurious Elevations in glycosylated hemoglobin (HbA1) secondary to hypertriglyceridemia. Arch Intern Med 1982;142:1370–1.
Garrib A, Griffiths W, Eldridge P, Hatton R, Worsley A, Crook M. Artefactually low glycated haemoglobin in a patient with severe hypertriglyceridaemia. J Clin Pathol 2003;56:394–5.
Rodriguez-gutierrez R, Mancillas-adame LG, Rodr guez-tamez G, Gonzalez-colmenero AD, Solis-pacheco RC, Elizondoplazas AS, et al. Hypertriglyceridemia and its association with HbA1c test: a Prospective in vivo controlled study. Int J Endocrinol 2019;2019:4784313.
Tharmaraj D, Kerr PG. Haemolysis in haemodialysis. Nephrology 2017;22:838–47.
Choi S, Lee Y. Association between total bilirubin and hemoglobin A1c in Korean type 2 diabetic patients. J Korean Med Sci 2012;27:1196–201.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-9.
Cohen G, Livovsky DM, Kapitulnik J, Sasson S. Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells. Rev Diabet Stud 2006;3: 127-33.
Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N, et al. High total bilirubin as a protective factor for diabetes mellitus: an Analysis of NHANES Data From 1999-2006. J Clin Med Res 2010;2:201-6.
Zheng CM, Ma WY, Wu CC, Lu KC. Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta 2012;413:1555-61.
Copur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, et al. Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. J Diabetes Complications 2020;34:107707.
Vos FE, Schollum JB, Walker RJ. Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease. NDT Plus 2011;4:368–75.
Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N. Glycated albumin versus glycated hemoglobin as a glycemic indicator in diabetic patients on peritoneal dialysis. Int J Mol Sci 2016;17:619.
Speeckaert M, Biesen W Van, Delanghe J, Slingerland R, Wiecek A. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?. Nephrol Dial Transpl 2014;29:2167–77.
Gai M, Merlo I, Dellepiane S, Cantaluppi V, Leonardi G, Fop F, et al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif 2014;38:68–73.
Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev 2020;41:756-74.
Riddlesworth TD, Beck RW, Gal RL, Connor CG, Bergenstal RM, Lee S, et al. Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control. Diabetes Technol Ther 2018;20:314-6.
Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose management indicator (GMI): A New term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018;41:2275-80.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from The International Consensus on Time in range. Diabetes Care 2019; 42:1593-603.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
